116: Can Weight Loss Medications (GLP1s) Reduce Breast Cancer Risk?

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. 

We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. 

Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. 

If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?

References

1. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.
2. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.
3. Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.
4. GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.
5. GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.
6. Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.
7. Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.
8. GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.
9. Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.
10. GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.

Transcript

Welcome And The Big Question

SPEAKER_00 0:04

Hi, welcome to your checkup. We are the patient education podcast where we bring conversations from the doctor's office to your ears. On this podcast, we try to bring medicine closer to its patients. I'm Ed Delesky, a family medicine doctor in the Philadelphia area. And I'm Nicole Ruffo, I'm a nurse. And we are so excited you were able to join us here again today. So what are we going to talk about today, Nick? So what are we going to talk about today, Nick?

SPEAKER_01 0:30

Today we're going to talk about a fun little study that just came out talking about if weight loss medications can reduce your risk. What did I just say? Reduce.

SPEAKER_00 0:42

Reduce.

SPEAKER_01 0:42

Reduce.

SPEAKER_00 0:43

I'm leaving it in. It keeps us real.

SPEAKER_01 0:45

Reduce your risk. Can reduce breast cancer risk.

SPEAKER_00 0:49

You said reduce again.

SPEAKER_01 0:50

I know I did that all back. Oh, okay. All right. Okay. Can weight loss medications reduce your risk of breast cancer?

SPEAKER_00 0:58

Yeah. Fascinating question. Really wasn't on my radar. Um, I actually thought about this shout-out. I don't know if she listens. One of my patients actually sent this to me in the portal. Um, my nurse patients. So that was cool. Kudos to you because now we're talking about it this week. It's been getting a lot of attention recently because a new study from researchers at Penn Medicine, Shout Out Philly, found out that women taking GLP1 medications appeared to have a lower risk of developing breast cancer.

SPEAKER_01 1:25

So before anyone rushes to their doctor to get a prescription to reduce your risk for breast cancer, there is an important cave caveat.

SPEAKER_00 1:35

Why did I say it like that? I don't know. Family.

SPEAKER_01 1:38

Fomley. An important thing to note is that this study does not prove that GLP1 medications prevent breast cancer. It does raise an interesting possibility and opens the door to a much bigger conversation about obesity, cancer risk, and why treating obesity can have benefits that go far beyond the number on the scale.

SPEAKER_00 2:02

So today we're going to talk about what the study found, what the best available evidence tells us, and why scientists are increasingly interested in the relationship between obesity and cancer. So let's start with the question. Why would anyone think a weight loss medication could affect cancer risk in the first place?

Why Obesity Raises Cancer Risk

SPEAKER_00 2:19

The answer actually begins with obesity. It's not just you, it's me. With obesity inherently. Many people think obesity primarily affects things like blood pressure, diabetes, cholesterol, sleep apnea, or joint pain. And if you've listened to us over the years, you would understand that too. And while all of that is true, obesity is also associated with an increased risk of many different types of cancers. Research oh my gosh, researchers estimate that obesity is linked to at least 13 different types of cancers, including breast cancer after menopause, colon cancer, endometrial cancer, kidney cancer, liver cancer, pancreatic cancer, and a few others. One reason for this is that fat tissue is much more than simply stored energy. Fat tissue is biologically active, it produces hormones, it releases inflammatory signals, it affects the immune system, and it influences how our bodies process and respond to insulin. So we'll break that down. First, inflammation. People living with obesity often have chronic, low-grade inflammation throughout the body. Unlike the inflammation you experience when you sprain an ankle or get an infection, this inflammation can quietly persist for years. Scientists believe chronic inflammation can damage cells and create an environment, a milieu, that may make it easier for cancer to develop. Nikki, what's next?

SPEAKER_01 3:47

We'll talk about the hormones next. So after menopause, fat tissue becomes one of the body's major sources of estrogen production. So higher estrogen exposure can increase the risk of certain hormone-sensitive breast cancers. Which is not good.

SPEAKER_00 4:04

Not good. Third is insulin resistance. Many people with obesity develop insulin resistance, which causes the body to produce more insulin. Higher levels of insulin and related growth signals can stimulate cell growth and may contribute to cancer development. And finally, obesity may affect how effectively the immune system identifies and eliminates abnormal cells before they become cancerous. So, in short, obesity influences multiple systems in the body that are involved in cancer development. And that is why researchers have become so interested in whether treating obesity could potentially reduce cancer risk.

What GLP-1 Medications Do

SPEAKER_00 4:42

We've talked about these medicines a lot, but we'll give a brief overview if you're new joining us here. But we'll go over here. We will talk about what GLP1 medications are so that people can understand more. These medications go by the name of Ozempic, Wagovi, Munjaro, Zeppound, Foundeo. These medications help regulate appetite dysregulation. They, for a period of time, slow stomach emptying, improve blood sugar control, and do so many other things, is what we're learning. Originally developed for diabetes, they have become important tools in obesity treatment because they address some of the biological drivers of excess weight and appetite dysregulation. As these medications became more widely used, researchers began asking an important question. If obesity contributes to cancer risk, could effective treatment of obesity help lower that risk? And that's where today's story begins.

What Trials Say About Safety

SPEAKER_00 5:33

So before we dive into the new study that's caught the eye in the news, discussing Penn's study, shout-out lead author McDonald, let's start with the strongest evidence available currently. For years, some people worried that GLP1 medications might increase the risk of certain cancers. It was basically more of just a theory of biological plausibility rather than anything grounded in data. So researchers have now looked at this question in large analyses of randomized controlled trials involving tens of thousands of patients. The research, the reassuring news is that these studies have consistently found no evidence that GLP1 medications increase breast cancer risk. And that's an important point. The strongest evidence we have today suggests that these medications do not appear to raise the risk of developing breast cancer. However, there's a limitation. Most of the trials lasted only a few years and were designed to study diabetes, weight loss, or cardiovascular outcomes, not cancer. Because cancer often develops over many years, researchers continued to study the question long term.

The Penn Observational Study Findings

SPEAKER_00 6:39

So now let's talk about the new study that's been caught in the news. Researchers at Penn Medicine examined over 100,000 women with overweight or obesity who underwent breast imaging. They compared women who had used GLP1 medications with similar women who had not used them. What they found was striking. Women using GLP1 medications had lower rates of breast cancer. Even after accounting for factors such as age, race, body mass indexed, breast density, and diabetes status, the association remained. The reduction was significant enough to get the attention of the lay media and the medical community. But there's a crucial distinction we should make. This was an observational study. What I told you earlier about the studies explained that there is no increased risk were randomized control trials, the top of the food pyramid, if you will, when it comes to research. Researchers observed what happened in the real world, but they did not randomly assign women to take the medicine or not. And because of that, the study can show an association, but cannot prove cause and effect. This is one of the most important concepts in medical research. Just because two things occur together does not necessarily mean one caused the other. I like to say this in clinic visits, saying that to describe this as the sun does not cause broken arms just because more people are outside when the sun is out and children are riding bikes and scooters and skateboards, the sun does not cause broken arms. Still, the findings are intriguing, and the Penn study is not alone. Several other recent observational studies have reported similar signals suggesting lower rates of certain breast cancers among women using GLP1 medications. Some studies have also suggested improved outcomes among women who already had breast cancer. And again, these findings are promising, but they're not definitive.

Which Breast Cancers Show A Signal

SPEAKER_00 8:34

A quick note about the type of breast cancer researchers are talking about not all breast cancers are the same. Some breast cancers have receptors on their cells that respond to hormones like estrogen or progesterone. These are called hormone receptor positive or HR positive breast cancers. You can think of these receptors almost like locks that can be opened by certain hormones. When these hormones are present, they can help stimulate cancer growth. Interestingly, some of the newer studies looking at GLP1 medications have found the strongest signal for reduced risk in hormone receptor positive breast cancer rather than other breast cancer subtypes. Researchers aren't exactly sure why. One possibility is that obesity can increase estrogen exposure, particularly after menopause, because fat tissue becomes an important source of estrogen production. If treating obesity leads to healthier hormone levels and improved metabolic health, that could potentially influence the risk of these hormone-sensitive cancers. It's important to remember that this is still an area of active research, and scientists are continuing to investigate exactly how these relationships work.

Theories On Why Risk May Drop

SPEAKER_00 9:43

So, Nikki, can you explore a little bit about why this might be happening, at least as they've postulated?

SPEAKER_01 9:50

There are a few different working theories. The simplest explanation is just the weight loss itself. If obesity is contributing to an increased cancer risk, then reducing obesity may have a reduced cancer risk. So that alone could explain many of the findings. Another is possibly that it involves insulin resistance, because with insulin resistance, these medications improve how the body responds to insulin and can often lower insulin levels. And because insulin-related growth signals, that's also another mouthful, may contribute to cancer development. Improving metabolic health could potentially play a role in decreasing the overall risk. The next thought is around inflammation and studying whether these medications are reducing inflammation in ways that may be beneficial to decreasing your cancer risk. And finally, some studies have explored whether GLP1 signaling may directly influence cancer biology. So at this point, it's too early to know how important they can play a direct role. So for now, most experts believe that the greatest benefit is likely related to improvements in the weight and metabolic health.

Practical Takeaways And Big Picture

SPEAKER_00 11:04

So what should we take away from all of this today? First, obesity is much more than body weight. It affects hormones, inflammation, metabolism, and many aspects of health long term. Second, current evidence suggests that GLP1 medications do not increase breast cancer risk. That's reassuring. Third, newer studies are raising the possibility that medications may reduce the risk of certain breast cancers, particularly hormone-sensitive breast cancers. But we're not there yet. We're not at the point where doctors prescribe these medications for cancer prevention. More research is absolutely needed. And I think that's what everyone is excited to see next. And finally, the biggest lesson may not be about the medications themselves. The bigger lesson here is that treating obesity matters. Whether through lifestyle changes, medications, surgery, or a combination of approaches, improving metabolic health can have benefits that extend far beyond the number on a

Philly Car Tow Story Time

SPEAKER_00 12:05

scale. And now for the banter. Probably with the towing of the car.

SPEAKER_01 12:14

Yeah, our first event of the weekend.

SPEAKER_00 12:16

Yeah, I felt like that was a nice way to wake up Friday morning. Um, I start at 7 a.m. So I have to like get out, um, be walking to my car by like 610 or whatever. And I'm walking around the corner, and all of a sudden I'm like, oh, my car isn't there. And in Philadelphia, I wondered immediately two things. I wondered, one, someone took it. It's gone.

SPEAKER_01 12:41

Very likely.

SPEAKER_00 12:42

Or two, my good friends at the PPA slash the police took my vehicle. Maybe some would argue stole my vehicle.

SPEAKER_01 12:53

The PPA or criminals.

SPEAKER_00 12:57

So I try to keep my cool. I stay calm. I immediately call my wife. Me. Can you declare? Yeah, thank you. And um I say, someone that my car is not here. It's like, oh, great. So we walk back. It was literally right around the corner. She steps outside, she's about ready to walk Ollie. And you look it up. And where is it?

SPEAKER_01 13:21

It's in South Philly in lot 10 at the PPA.

SPEAKER_00 13:25

Yeah. So for you know, it turns out that maybe, you know, they just took my car. We won't talk about it too um too much about the why, but my car was missing. Um, this can happen for any number of various reasons. I'm hoping to consider it a courtesy toe when they have to do some work in the area. And I wasn't made aware that they didn't notify you. They did not notify me that the big wink. Yes, big wink. They did not notify me that the car was being moved or that it couldn't be there, and they just took it. Which can happen. And then in reading about this, apparently you they can take the car, move it to an illegal spot, plop it there, and then circle around a little bit until it satisfies the illegal nature of the car being there, and then they can scoop it up and impound it for another ticket.

SPEAKER_01 14:13

Yeah, that happened to someone I used to work with.

SPEAKER_00 14:16

That's ridiculous. You had some heated things to say about the PPA.

SPEAKER_01 14:20

I did. The PPA are just like first, they're not like governed by Philadelphia in any capacity. They're just like rogue and like doing their own thing. So they're like, we'll tow your car, we'll move your car, put it in an illegal spot, and then give you a ticket or tow your car from the illegal spot that they moved it to. And you know, everyone's like biggest arch nemesis in this city is the PPA, like it is the people versus the PPA, Philadelphia versus the PPA.

SPEAKER_00 14:56

Yeah.

SPEAKER_01 14:57

And I genuinely think that if any sort of like criminal activity was solely directed to the PPA, we would find peace in this city. Or at least it would be the city of brotherly love. I feel like people like if people who don't like live here or like know Philadelphia, but they do know the Philadelphia sports fans, and they think that the sports fans are passionate, like we're also very passionate about hating the PPA. So I feel like we could all come together in harmony, and then we would all be like singing that song. What was that like? Wasn't it like a Coca-Cola commercial? It's like an iconic commercial from like the 70s, I'm pretty sure.

SPEAKER_00 15:47

And it became like a global like they're in like Italy or something.

SPEAKER_01 15:52

No, they're like, wait, I feel like I can picture it. Like that, that will be us in Philadelphia. We would all be on Broad Street, be friends, singing, singing. No, you know what the song is? No, you know what I'm talking about?

SPEAKER_00 16:07

I don't know what you're talking about.

SPEAKER_01 16:08

It's like an iconic, um, I don't even know what to search for.

SPEAKER_00 16:12

Not that iconic.

SPEAKER_01 16:13

World, no, it is like World Peace commercial? Was it was it a Coca-Cola commercial? Commercial. World Peace commercial song? World Cook Peace. It's like a bunch of people singing.

SPEAKER_00 16:32

If with someone in like advertising or something. Oh no. Singing now, American ad jingles ever made. In 1971, Coca-Cola showed a little bit.

SPEAKER_01 16:43

It was Coca-Cola.

SPEAKER_00 16:51

Yeah.

unknown 16:55

It had young people.

SPEAKER_01 16:56

Yeah, people were all sitting on the standing on a hill. You've never seen this? I'd like to buy the world a colour. Yeah. Oh, yeah, yeah, yeah. This will be us. This will be the Philadelphians. If they brought the PPA down.

SPEAKER_00 17:15

Yeah, maybe. Bring it down. They really do. So then we have to go down there.

SPEAKER_01 17:22

You never saw this commercial? This will be us. Imperfect harmony in Philadelphia by bringing down the PPA.

SPEAKER_00 17:41

We're not suggesting anyone should like be violent towards any PPA workers, by the way. We're not suggesting that.

SPEAKER_01 17:45

Yeah, no, not at all.

SPEAKER_00 17:51

I feel like this would fall under the category of like when my boss said, don't say anything stupid on your podcast.

SPEAKER_01 17:57

Um Yeah, we're not condoning violence. I'm just saying, like, hypothetically, if there's something that we all can agree on as a population, it's that.

SPEAKER_00 18:07

They could be more lenient.

SPEAKER_01 18:08

Nobody likes the PPA.

SPEAKER_00 18:10

Maybe the PPA.

SPEAKER_01 18:11

People that get paid by the PPA don't even like the PPA.

SPEAKER_00 18:13

That's a good point. You're saying that people, not even the workers, it's the organization. Yeah.

SPEAKER_01 18:19

Not to like the people who are out patrolling the streets. You know, they're just doing their job. But like whoever the exultant ruler of the PPA is, we gotta bring them down.

SPEAKER_00 18:29

Kibosh, squash odd.

SPEAKER_01 18:30

Not violently, of course. Just, you know, we'll stage a coup.

SPEAKER_00 18:33

Perhaps with strongly worded letters.

SPEAKER_01 18:35

Yeah.

SPEAKER_00 18:35

And subtlety and silence.

SPEAKER_01 18:38

Yeah.

SPEAKER_00 18:39

In shadow. So we go down there and we meet some nice people. Um, and what? We're like going in there, it's like a trailer and several gates.

SPEAKER_01 18:50

It was my first time. It was your first time. Maybe first time at the PPA.

SPEAKER_00 18:53

What do you think? What'd you think of that?

SPEAKER_01 18:54

Or at the impound lot, I guess.

SPEAKER_00 18:56

You did not have a wait long wait, so that was good. It was so nice that you came with me.

SPEAKER_01 19:00

Yeah, I mean, we were all in all, it was like an hour. Yeah. And it wasn't that bad.

SPEAKER_00 19:04

Could have been so much worse.

SPEAKER_01 19:05

I um I mean, I thought it was gonna be like a building, like how it is here when you like whatever it is here.

SPEAKER_00 19:15

No.

SPEAKER_01 19:16

I know it's a trailer.

SPEAKER_00 19:18

Yep, those poor people.

SPEAKER_01 19:20

And it's very inefficient.

SPEAKER_00 19:24

It's extremely inefficient.

SPEAKER_01 19:25

Well, the hours on Friday and Saturday are like 7 a.m. to 3 a.m.

SPEAKER_00 19:28

God bless.

SPEAKER_01 19:31

It's not it's so inefficient because there are the first two windows, and you go and you're like, this is what I'm here to do. Everyone's there to get their car because it's just all in a lot. It's a trailer and a parking lot. And then I don't know, he like does whatever. And then he's like, okay, now you have to go down to one of the next windows. There's two sets of windows that you have to go to to either like pay your ticket or like whatever. If you could just do it all at the one window, there could be five people going at once.

SPEAKER_00 20:01

Not to mention that most people have their license, they have their like insurance cards and registration. In their car.

SPEAKER_01 20:09

So you have to go to the first window. Then you have to go to the second window where you do whatever. And then from the second window, if you need to go to your car to get your stuff, then you have to take this paper to the lot, go get your stuff, then come back in line, which for us there really wasn't one, but that one time you went.

SPEAKER_00 20:25

Yes, everyone re-got back in the initial line. So the line was double as long as it needed to.

SPEAKER_01 20:31

And I felt everyone who got back in line had to go to the second set of windows, not the first set, to do the initial part.

SPEAKER_00 20:37

But they didn't know that at the time.

SPEAKER_01 20:39

Also, the amount of people I don't know, if there were maybe what, like five sets of people there to get their car.

SPEAKER_00 20:46

Yeah.

SPEAKER_01 20:47

And like us and maybe like one of those other people who were next to us went like bang bang, got their stuff and left. Everyone else, it was like they didn't have the registration, they didn't have a license. This one guy was going around like asking everyone there if they had a license, if we could drive his car off the lot for him.

SPEAKER_00 21:05

Yes. I'm like, they did what are you doing? I I know I was caught between like trying to be a good Samaritan, but also once I realized how intense of an operation this was, yeah, it wasn't gonna be the mission for me.

SPEAKER_01 21:17

Yeah.

SPEAKER_00 21:18

So there's also a lot of people outside today. Um, happy pride. And so I get there and like there's gates. There's like sliding gates that are locked.

SPEAKER_01 21:29

Only the driver can come back.

unknown 21:30

Right.

SPEAKER_01 21:31

Like, okay, maybe I'm I'll just stand here. I know, yeah. You were like South Philly.

SPEAKER_00 21:36

And then they're like, all right, go to the car, get the registration, get the light, get the insurance card, which I actually think are still outside of the car, by the way. Um, you might need them. Who knows? Who knows? And then I walk back and they tell me to go to the first gate and wait, and go to the second gate, now go back inside. And then you know, they're actually really nice inside and they help me out and they tell me how to go about things because I don't believe I should be paying for this. And And then we go back outside, and now we're at this gate again. It's like a chain link fence with barbed wire on top. And they're like, all right, go get your car. So walk to this next gate. So I walk into the next gate and like get in this vehicle. I'm like, my car is right there. I can walk to my car. And they're like, hmm. They just stare at me and I stare at them. And I say to myself, self? I guess I'm getting in this car. So then they proceed to roll up 20 feet and they're like, all right, can I have that paper? They take the paper, they scan it, and they're like, all right, go get your car. And I'm like, why? Why did I need to do that? So then I get in the car, I have this giant sticker, which just shows that my car has gone, I don't even know. And I have this giant sticker on the windshield, and I'm driving out in shame, but then the gate opens, and it I feel free. I've never been to jail, I don't plan on it, but like the gate opens, and then the sun got brighter. It was a hot day, and then I roll out, and who's there waiting for me? My Nikki. And you hop in the car, and then we we zoom out of there safely and we go pack up and head southeast. My goodness. Wow.

SPEAKER_01 23:15

Head southeast.

SPEAKER_00 23:18

Yeah, that was an experience that I wish I didn't have to have.

SPEAKER_01 23:24

Yeah. It could have been worse out there. We were like in and out and out.

SPEAKER_00 23:28

Oh my gosh. Yeah. Worse would have been if my car was stolen.

SPEAKER_01 23:30

I was fully prepped. Well, worse, yeah. That would be if your car was stolen. At least we knew where it was. But like if we got there, and I was like, everyone's gonna be coming here after work, just like we are. There's gonna be 45 people in this line. We're gonna have to do the whole rig and roll, get back into four different lines.

SPEAKER_00 23:49

Deconstruct the line.

SPEAKER_01 23:50

Like tell people we're not gonna go to the beach tonight because we're gonna be here until like 10 o'clock. But it was fine.

SPEAKER_00 23:57

It was fine. We made it, and there are worse things in the world, and it's good. Um then Thursday, so like I've been counting my things, and I'm gonna consider that. What what did we say my third thing was? Because my second thing, which happened before the car, was I'm walking across this like a street.

SPEAKER_01 24:12

Oh my god.

SPEAKER_00 24:12

I did not tell Nikki during the day. I told her when we got home because I didn't want her to be like worried. And I'm like walking to the gym and a usual street, but I'm like in the way of a left-turning car that started to speed up, and he like didn't even stop. So I had to run out of the way because he like wouldn't stop. So then he turned around and he like apologized and had my headphones in, and I was like, Hey, you know, all right, thanks. But then my knee kind of hurt. I've been working on my some knee pain, so that kind of stinks. But like, I'm glad I didn't get nuked by a truck.

SPEAKER_01 24:43

Yeah, same.

SPEAKER_00 24:45

That would have been a bummer. Ollie is also what was that? Ollie would have been pissed too. Yeah, well, people gotta be careful. Who's my we had some like small inconvenient thing that happened that we called my third thing?

SPEAKER_01 25:03

He like jumped on the couch, but like fell a little. Yes.

SPEAKER_00 25:05

But like he's was fine. He's he's fine. That was the third thing. So we're good. We're clean. We're clean and clear. My gosh. We um we got caught on the beach in a thunderstorm.

SPEAKER_01 25:17

Yeah.

SPEAKER_00 25:19

Torrential romantic downpour. That was cute. All right. I actually, that was about 14 minutes. I think we're good.

SPEAKER_01 25:26

That was 14 minutes.

SPEAKER_00 25:27

Yeah, why don't we um why don't we lock in? Alrighty.

Where To Find Us And Goodbye

SPEAKER_00 25:31

So thank you for coming back to another episode of your checkup. Hopefully, you were able to learn something for yourself, a loved one, or a neighbor. You can find us on Threads, you can email us, your checkuppod at gmail.com, or find us on Instagram. You can share this with your neighbor, or whatever. Most importantly, stay healthy, my friends.

SPEAKER_01 25:52

Whatever.

SPEAKER_00 25:53

Stay healthy, my friends. Until next time, I'm Ed Delesky.

SPEAKER_01 25:56

I'm Nicola Rufo.

SPEAKER_00 25:57

Thank you and goodbye.

SPEAKER_01 25:58

Bye.